Gain Therapeutics reported a new Parkinson’s disease therapeutic discovered using a hybrid AI and physics‑based modeling approach. Gene Mack presented a compound that allosterically binds and stabilizes a dysfunctional enzyme implicated in Parkinson’s pathology, reportedly restoring enzymatic function and reducing neuroinflammation in preclinical models. The announcement highlights computationally driven target identification and optimization as a route to rapid lead generation for neurodegenerative disease.